Genentech TNKase
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Tenecteplase approved June 2 for reduction of mortality associated with acute myocardial infarction. TNKase is the first thrombolytic that "can be administered over five seconds in a single dose," the firm says. Genentech's older t-PA agent, Activase (alteplase), is dosed as either a three-hour or 90-minute accelerated infusion. TNKase will debut at the same direct-to-wholesaler price as Activase: $2,200 per dose. FDA's approval letter directs the firm to begin enrollment by September 30 for a registry study of African-American, Hispanic, and low body weight patients treated with TNKas
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.